AtaiBeckley Completes Patient Dosing In Depression Drug Trial, Expects Depression Treatment Trial Data In Late 2026
AtaiBeckley Inc. (NASDAQ: ATAI ) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that the last patient has been dosed in Elumina, its Phase 2b clinical trial evaluating VLS-01 in adults living with treatment-resistant depression (TRD). The study randomized 156 patients, with topline data expected in Q4 2026.
AtaiBeckley Inc. (NASDAQ: ATAI ) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that the last patient has been dosed in Elumina, its Phase 2b clinical trial evaluating VLS-01 in adults living with treatment-resistant depression (TRD).
The study randomized 156 patients, with topline data expected in Q4 2026.